Beam Therapeutics Inc.
BEAM
$15.47
$0.845.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -83.18% | 328.73% | 339.83% | 370.57% | 520.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -83.18% | 328.73% | 339.83% | 370.57% | 520.01% |
| Cost of Revenue | -15.96% | 5.88% | 11.69% | 22.19% | 40.37% |
| Gross Profit | -409.52% | 81.28% | 79.42% | 77.10% | 76.20% |
| SG&A Expenses | -4.53% | 31.05% | 34.95% | 30.42% | 33.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.55% | 10.93% | 16.35% | 23.92% | 38.76% |
| Operating Income | -135.47% | 54.14% | 51.64% | 49.70% | 47.86% |
| Income Before Tax | -187.21% | 54.53% | 56.26% | 57.38% | 54.09% |
| Income Tax Expenses | -97.14% | 40.50% | -58.80% | -59.94% | -59.94% |
| Earnings from Continuing Operations | -184.28% | 54.22% | 56.29% | 57.41% | 54.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.28% | 54.22% | 56.29% | 57.41% | 54.16% |
| EBIT | -135.47% | 54.14% | 51.64% | 49.70% | 47.86% |
| EBITDA | -151.57% | 57.65% | 55.31% | 53.46% | 51.76% |
| EPS Basic | -144.95% | 58.80% | 60.96% | 60.93% | 54.77% |
| Normalized Basic EPS | -156.13% | 65.70% | 69.07% | 64.39% | 62.71% |
| EPS Diluted | -139.79% | 57.80% | 60.05% | 60.00% | 53.76% |
| Normalized Diluted EPS | -150.40% | 64.84% | 68.30% | 63.58% | 61.85% |
| Average Basic Shares Outstanding | 6.73% | 9.67% | 11.79% | 12.10% | 10.16% |
| Average Diluted Shares Outstanding | 6.09% | 10.29% | 12.43% | 12.75% | 10.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
